In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Viridian Therapeutics Inc’s stock clocked out at $12.65, down -1.17% from its previous closing price of $12.80. In other words, the price has decreased by -$1.17 from its previous closing price. On the day, 1.87 million shares were traded. VRDN stock price reached its highest trading level at $13.01 during the session, while it also had its lowest trading level at $12.27.
Ratios:
To gain a deeper understanding of VRDN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.43 and its Current Ratio is at 15.43. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $27 from $37 previously.
Needham reiterated its Buy rating for the stock on September 11, 2024, while the target price for the stock was revised from $30 to $38.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 27 ’24 when Beetham Thomas W. bought 5,000 shares for $23.41 per share. The transaction valued at 117,050 led to the insider holds 6,000 shares of the business.
Mahoney Stephen F. bought 21,400 shares of VRDN for $499,262 on Sep 27 ’24. The President and CEO now owns 21,400 shares after completing the transaction at $23.33 per share. On Sep 13 ’24, another insider, Fairmount Funds Management LLC, who serves as the Director of the company, bought 1,600,000 shares for $18.75 each. As a result, the insider paid 30,000,000 and bolstered with 3,445,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1030785216 and an Enterprise Value of 525204608. For the stock, the TTM Price-to-Sale (P/S) ratio is 3435.96 while its Price-to-Book (P/B) ratio in mrq is 2.12. Its current Enterprise Value per Revenue stands at 1739.088 whereas that against EBITDA is -1.76.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.63, which has changed by -0.16556728 over the last 52 weeks, in comparison to a change of 0.05279863 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is -16.05%, while the 200-Day Moving Average is calculated to be -29.86%.
Shares Statistics:
It appears that VRDN traded 967.01K shares on average per day over the past three months and 1409470 shares per day over the past ten days. A total of 80.99M shares are outstanding, with a floating share count of 73.28M. Insiders hold about 10.07% of the company’s shares, while institutions hold 104.69% stake in the company. Shares short for VRDN as of 1743379200 were 10159066 with a Short Ratio of 10.51, compared to 1740700800 on 9567139. Therefore, it implies a Short% of Shares Outstanding of 10159066 and a Short% of Float of 14.109999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
